COPD, COPD III/IV
Conditions
Keywords
Inhaled, nitroglycerin
Brief summary
this study aims to investigative the benefits of using nebulized nitroglycerin in improving respiratory functions in patients of late stage COPD
Detailed description
the inhaled nitroglycerin is expected to make vasodilatation of the pulmonary arteries and arterioles which are constricted in late stages of COBD leading to ventilation/perfusion mismatching and further aggravating COPD. it will also help in delivering better antibiotic concentrations to the alveoli which help in better control of infection.
Interventions
Inhaled nitroglycerin
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult patient's ≥ 18 years old COPD exacerbation with respiratory failure and Echo evidenced presence of pulmonary hypertension (defined as mean pulmonary artery pressure \> 20 mmHg)
Exclusion criteria
* Profound left ventricular failure, as the decrease in pulmonary vascular resistance results in an increase in left ventricular preload. This may worsen cardiogenic pulmonary edema. * Pregnant female patients * Patient with hypersensitivity to nitroglycerin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in pulmonary functions | 5 days after start of nebulized nitroglycerin | Change in pulmonary functions Defined as: * Reduction of PaCO2 in arterial blood gases from admission value. * increase in Pao2 from admission value. |
Secondary
| Measure | Time frame |
|---|---|
| Number of days on mechanical ventilation | 5 days after start of nebulized nitroglycerin |
| Dose of vasopressor therapy | 5 days after start of nebulized nitroglycerin |
| Reduction of WBC count | 10 days after start of nebulized nitroglycerin |
| Mortality rate | 10 days after start of nebulized nitroglycerin |
Countries
Egypt